Skip to content
10-Q

Quarterly Report

ALNYLAM PHARMACEUTICALS, INC. ALNY

0001628280-25-047345

← back to feed
Filed
Oct 30, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Oct 24, 2025 132.11M sh
Shares Diluted Q3 2025 · Sep 30, 2025 137.35M sh
Shares Diluted Q3 2025 · Sep 30, 2025 134.15M sh
Shares Diluted Q3 2025 · Sep 30, 2024 128.59M sh
Shares Diluted Q3 2025 · Sep 30, 2024 127.16M sh
Capex Q3 2025 · Sep 30, 2025 $35.41M
Capex Q3 2025 · Sep 30, 2024 $25.18M
Operating Cash Flow Q3 2025 · Sep 30, 2025 $360.53M
Operating Cash Flow Q3 2025 · Sep 30, 2024 $86.35M
Cash And Equivalents Q3 2025 · Sep 30, 2025 $1.49B
Cash And Equivalents Q3 2025 · Dec 31, 2024 $966.43M
Cash And Equivalents Q3 2025 · Sep 30, 2024 $1.1B
Stockholders Equity Q3 2025 · Sep 30, 2025 $233.89M
Stockholders Equity Q3 2025 · Jun 30, 2025 $250.59M
Stockholders Equity Q3 2025 · Mar 31, 2025 $115.44M
Stockholders Equity Q3 2025 · Dec 31, 2024 $67.09M
Stockholders Equity Q3 2025 · Sep 30, 2024 $32.35M
Stockholders Equity Q3 2025 · Jun 30, 2024 −$3.07M
Stockholders Equity Q3 2025 · Mar 31, 2024 −$219.27M
Stockholders Equity Q3 2025 · Dec 31, 2023 −$220.64M
Current Liabilities Q3 2025 · Sep 30, 2025 $1.56B
Current Liabilities Q3 2025 · Dec 31, 2024 $1.19B
Total Liabilities Q3 2025 · Sep 30, 2025 $4.62B
Total Liabilities Q3 2025 · Dec 31, 2024 $4.17B
Current Assets Q3 2025 · Sep 30, 2025 $3.95B
Current Assets Q3 2025 · Dec 31, 2024 $3.3B
Total Assets Q3 2025 · Sep 30, 2025 $4.85B
Total Assets Q3 2025 · Dec 31, 2024 $4.24B
Eps Diluted Q3 2025 · Sep 30, 2025 $1.84
Eps Diluted Q3 2025 · Sep 30, 2025 $0.95
Eps Diluted Q3 2025 · Sep 30, 2024 −$0.87
Eps Diluted Q3 2025 · Sep 30, 2024 −$1.53
Eps Basic Q3 2025 · Sep 30, 2025 $1.91
Eps Basic Q3 2025 · Sep 30, 2025 $0.98
Eps Basic Q3 2025 · Sep 30, 2024 −$0.87
Eps Basic Q3 2025 · Sep 30, 2024 −$1.53
Sga Expense Q3 2025 · Sep 30, 2025 $322.08M
Sga Expense Q3 2025 · Sep 30, 2025 $885.34M
Sga Expense Q3 2025 · Sep 30, 2024 $220.99M
Sga Expense Q3 2025 · Sep 30, 2024 $680.19M
Rd Expense Q3 2025 · Sep 30, 2025 $358.81M
Rd Expense Q3 2025 · Sep 30, 2025 $947.56M
Rd Expense Q3 2025 · Sep 30, 2024 $270.93M
Rd Expense Q3 2025 · Sep 30, 2024 $826.06M
Net Income Q3 2025 · Sep 30, 2025 $251.08M
Net Income Q3 2025 · Sep 30, 2025 $127.33M
Net Income Q3 2025 · Jun 30, 2025 −$66.28M
Net Income Q3 2025 · Mar 31, 2025 −$57.48M
Net Income Q3 2025 · Sep 30, 2024 −$111.57M
Net Income Q3 2025 · Sep 30, 2024 −$194.39M
Net Income Q3 2025 · Jun 30, 2024 −$16.89M
Net Income Q3 2025 · Mar 31, 2024 −$65.94M
Operating Income Q3 2025 · Sep 30, 2025 $367.98M
Operating Income Q3 2025 · Sep 30, 2025 $369.86M
Operating Income Q3 2025 · Sep 30, 2024 −$76.91M
Operating Income Q3 2025 · Sep 30, 2024 −$71.73M
Cost Of Revenue Q3 2025 · Sep 30, 2025 $197.23M
Cost Of Revenue Q3 2025 · Sep 30, 2025 $409.44M
Cost Of Revenue Q3 2025 · Sep 30, 2024 $81.98M
Cost Of Revenue Q3 2025 · Sep 30, 2024 $203.86M
Revenue Q3 2025 · Sep 30, 2025 $1.25B
Revenue Q3 2025 · Sep 30, 2025 $2.62B
Revenue Q3 2025 · Sep 30, 2024 $500.92M
Revenue Q3 2025 · Sep 30, 2024 $1.66B